Business
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026 Initial WVE-007 240 mg single-dose data reported in 2025 demonstrated improved body composition with fat loss similar to GLP-1 at three months with muscle preservation and the potential for once or twice-yearly dosing; higher dose
About this update from Wave Life Sciences Ltd.
[{"type":"image","alt":"Wave Life Sciences USA, Inc.","displaySize":"","headline":null,"caption":"Wave Life Sciences USA, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bBn7PJO.Wa13q4jNzDNEcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6","width":300,"height":161}},"lazy":false},{"type":"text","content":"Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026","length":269,"tagName":"p"},{"type":"text","content":"Initial WVE-007 240 mg single-dose data reported in 2025 demonstrated improved body composition with fat loss similar to GLP-1 at three months with muscle preservation and the potential for once or twice-yearly dosing; higher dose and longer follow-up data from INLIGHT anticipated in 2026, including three-month 400 mg and six-month 240 mg data on track for this quarter","length":371,"tagName":"p"},{"type":"text","content":"Extending leadership in RNA editing following first-ever successful clinical translation with WVE-006 for AATD, with multiple additional data updates from RestorAATion-2 on track for 2026; Wave expects to file CTA in 2026 for WVE-008 for nine million individuals living with homozygous PNPLA3 I148M liver disease in the U.S. and Europe","length":335,"tagName":"p"},{"type":"text","content":"Well capitalized with preliminary, unaudited cash and cash equivalents of ~$602 million as of December 31, 2025; expected cash runway into 3Q 2028","length":146,"tagName":"p"},{"type":"text","content":"Presentation and webcast at 44th Annual J.P. Morgan Healthcare Conference tomorrow, Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET","length":140,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today highlighted its strategic priorities for 2026, including acc...